Blockchain Registration Transaction Record

Annovis Bio to Present Buntanetap Data at CTAD 2026

Annovis Bio will present three buntanetap studies at CTAD 2026, highlighting Phase 3 design, AI blood-brain barrier prediction, and mechanism of action. Read more.

Annovis Bio’s upcoming presentations at CTAD 2026 underscore the growing momentum behind buntanetap, a multi-target oral therapy that could reshape the treatment landscape for Alzheimer’s and Parkinson’s diseases. By tackling multiple neurotoxic proteins simultaneously, buntanetap offers a novel approach that may halt disease progression rather than merely managing symptoms. The inclusion of AI-driven blood-brain barrier permeability predictions further highlights the company’s innovative edge in drug development. With a pivotal Phase 3 readout expected in early 2027 and an NDA on the horizon, these presentations could be a catalyst for investor confidence and partnership opportunities. For patients and caregivers, the progress signals hope for a convenient, once-daily oral treatment that addresses the underlying pathology of devastating neurodegenerative conditions.